J&J Acquires Phase III Antibiotic Via Peninsula Purchase
This article was originally published in The Pink Sheet Daily
Executive Summary
Johnson & Johnson is acquiring the Phase III injectable carbapenem antibiotic doripenem via the $245 mil. acquisition of Peninsula Pharmaceuticals
You may also be interested in...
Ortho-McNeil Gets FDA Approval For Complicated Intra-Abdominal/UTI Therapy Doribax
Studies of the novel injectable carbapenem antibiotic showed activity in several forms of Gram-positive and Gram-negative bacteria, including Pseudomonas.
Ortho-McNeil Gets FDA Approval For Complicated Intra-Abdominal/UTI Therapy Doribax
Studies of the novel injectable carbapenem antibiotic showed activity in several forms of Gram-positive and Gram-negative bacteria, including Pseudomonas.
J&J Submits NDA For Novel Antibiotic Doripenem
Drug could reach market by October 2007.